For example, despite aconsensus about the importance of HER2 as a predictor of a betteroutcome in localized and advanced disease,4 trastuzumab, an anti-HER2 monoclonal antibody, is not accessible tolow-income patients with breast cancer in many countries. The gene discussed is ERBB2; the disease is breast carcinoma.